microRNA-29b-3p attenuates diabetic nephropathy in mice by modifying EZH2
- PMID: 36692688
- DOI: 10.1007/s42000-022-00426-2
microRNA-29b-3p attenuates diabetic nephropathy in mice by modifying EZH2
Abstract
Objective: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease around the world. This study investigated the role of microRNA (miR)-29b-3p in DN and the mechanism of the miR-29b-3p/EZH2 axis in DN.
Methods: Peripheral blood samples of DN patients were collected and miR-29b-3p and EZH2 expression levels were evaluated using RT-qPCR. DN mouse models were successfully established, and then treated with miR-29b-3p overexpression or EZH2 silence. IL-1β, IL-6, and TNF-α levels were assessed by ELISA. Blood glucose, serum creatinine (Scr), 24-h urine volume, 24-h urine protein, and blood urea nitrogen (BUN) levels were examined by automatic biochemical analyzer detection. HE staining was performed to observe the renal histopathology, and TUNEL staining was implemented to test apoptosis in renal tissues. The binding relationship between miR-29b-3p and EZH2 was validated by using a bioinformatics website and dual luciferase reporter gene assay.
Results: miR-29b-3p was lowly expressed, and EZH2 was highly expressed in patients with DN. Overexpressing miR-29b-3p or silencing EZH2 attenuated renal dysfunction, suppressed inflammation and apoptosis, and relieved renal injuries in mice with DN. miR-29b-3p inhibited EZH2, and miR-29b-3p overexpression mitigated renal injuries in DN mice by repressing EZH2.
Conclusion: miR-29b-3p suppresses EZH2 expression thereby inhibiting the progression of DN in mice.
Keywords: Apoptosis; Diabetic nephropathy; Enhancer of zeste homolog 2; Inflammatory response; MicroRNA-29b-3p.
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Similar articles
-
miR-188-3p abolishes germacrone-mediated podocyte protection in a mouse model of diabetic nephropathy in type I diabetes through triggering mitochondrial injury.Bioengineered. 2022 Jan;13(1):774-788. doi: 10.1080/21655979.2021.2012919. Bioengineered. 2022. Retraction in: Bioengineered. 2024 Dec;15(1):2299558. doi: 10.1080/21655979.2024.2299558. PMID: 34847832 Free PMC article. Retracted.
-
MiRNA-133a-3p Attenuates Renal Tubular Epithelial Cell Injury via Targeting MALM1 and Suppressing the Notch Signaling Pathway in Diabetic Nephropathy.Cell Biochem Biophys. 2024 Sep;82(3):2401-2411. doi: 10.1007/s12013-024-01351-4. Epub 2024 Jun 15. Cell Biochem Biophys. 2024. PMID: 38878099
-
Histone methyltransferase enhancer of zeste 2 polycomb repressive complex 2 subunit exacerbates inflammation in depression rats by modulating microglia polarization.Bioengineered. 2022 Mar;13(3):5509-5524. doi: 10.1080/21655979.2022.2036892. Bioengineered. 2022. PMID: 35172677 Free PMC article.
-
Roles of microRNA-192 in diabetic nephropathy: the clinical applications and mechanisms of action.Front Endocrinol (Lausanne). 2023 Jun 15;14:1179161. doi: 10.3389/fendo.2023.1179161. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37396169 Free PMC article. Review.
-
MicroRNA-21 Silencing in Diabetic Nephropathy: Insights on Therapeutic Strategies.Biomedicines. 2023 Sep 20;11(9):2583. doi: 10.3390/biomedicines11092583. Biomedicines. 2023. PMID: 37761024 Free PMC article. Review.
Cited by
-
MiR-29b Alleviates High Glucose-induced Inflammation and Apoptosis in Podocytes by Down-regulating PRKAB2.Endocr Metab Immune Disord Drug Targets. 2024;24(8):981-990. doi: 10.2174/0118715303267375231204103200. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38204237 Free PMC article.
References
-
- Liu D, Zheng W, Pan S, Liu Z (2020) Concise review: current trends on applications of stem cells in diabetic nephropathy. Cell Death Dis 11(11):1000. https://doi.org/10.1038/s41419-020-03206-1 - DOI - PubMed - PMC
-
- Bonner R, Albajrami O, Hudspeth J, Upadhyay A (2020) Diabetic kidney disease. Prim Care 47(4):645–659. https://doi.org/10.1016/j.pop.2020.08.004 - DOI - PubMed
-
- Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22(Suppl 1):3–15. https://doi.org/10.1111/dom.14007 - DOI - PubMed
-
- Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R (2020) Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol 33(5):949–963. https://doi.org/10.1007/s40620-020-00803-3 - DOI - PubMed - PMC
-
- Yarahmadi A, Shahrokhi SZ, Mostafavi-Pour Z, Azarpira N (2021) MicroRNAs in diabetic nephropathy: From molecular mechanisms to new therapeutic targets of treatment. Biochem Pharmacol 189:114301. https://doi.org/10.1016/j.bcp.2020.114301 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical